Pneumonia, typhoid, malaria, tuberculosis…
This is where vaccines play a major role: they prevent infections and reduce the use and overuse of antibiotics. Ultimately, they slow the appearance and spread of antibiotic-resistant pathogens.
The WHO talks about vaccines that already exist but also are still being developed. “Vaccines already used against pneumococcal pneumonia, Haemophilus influenzae type B (the Hib bacteria, responsible for pneumonia and meningitis) and typhoid could prevent up to 106,000 deaths associated with AMR each year,” notes the agency. UN health agency in a press release.
Optimal use of existing vaccines could save:
33 million doses of antibiotics for the vaccine against Streptococcus pneumoniae (responsible for many diseases (ear infections, pneumonia, meningitis, etc.); 45 million doses for the vaccine against typhoid; 25 million doses for the vaccine against malaria. 730 billion dollars in savings
As for vaccines under development, “543,000 additional AMR-associated deaths could be avoided each year when new vaccines against tuberculosis (TB) and Klebsiella pneumoniae are developed and deployed globally.” So TB vaccines could have the biggest impact once developed, saving between 1.2 and 1.9 billion doses of antibiotics
On the financial side, the WHO estimates a reduction of $730 billion in hospital spending each year with better vaccination.
At the last United Nations General Assembly, leaders approved a 10% reduction by 2030 in the number of deaths associated with AMR each year. To achieve this, “a comprehensive, people-centered approach, applied across health systems, is needed to prevent, diagnose and treat infections. This approach recognizes vaccination as a central component of AMR prevention, and it is particularly effective when combined with other interventions.”
Marburg virus epidemic in Rwanda: what is this hemorrhagic fever?
Source: Destination Santé
Related News :